Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

BACKGROUND: Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials. In these analyses, we aimed to evaluate the safety and tolerability of galcanezumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Bangs, Mark E., Kudrow, David, Wang, Shufang, Oakes, Tina M., Terwindt, Gisela M., Magis, Delphine, Yunes-Medina, Laura, Stauffer, Virginia L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966798/
https://www.ncbi.nlm.nih.gov/pubmed/31952501
http://dx.doi.org/10.1186/s12883-020-1609-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966798/
https://www.ncbi.nlm.nih.gov/pubmed/31952501
http://dx.doi.org/10.1186/s12883-020-1609-7

Ejemplares similares